A previous study showed that the transfection of a VEGF-C mRNA construct strengthened the efficacy of immunotherapy against glioma.23 In our study here, VEGF-C mRNA delivery into the CSF increased the survival time of mice bearing gliomas and reduced tumor volume after RT. This evidence concerns the gene VEGFC and glioma.